{"chief_complaint_en": ["Bleeding"], "content": {"about": {"evidence_based_medicine_en": "", "formula_en": "<p>Addition of the selected points, see below:</p>", "more_info_en": "<div class='table-responsive' style='max-width: 710px;'> <table class='table table-bordered'> <tbody> <tr> <th>Category</th> <th>2 points</th> <th>1 point</th> <th>0 points</th> </tr> <tr> <td>Thrombocytopenia</td> <td>Platelet count fall &gt; 50% AND platelet nadir \u2265 20 \u00d7 10<sup>9</sup> L<sup>\u22121</sup></td> <td>Platelet count fall 30%\u201350% OR platelet nadir 10\u201319 \u00d7 10<sup>9</sup> L<sup>\u22121</sup></td> <td>Platelet count fall &lt; 30% OR platelet nadir &lt; 10 \u00d7 10<sup>9</sup> L<sup>\u22121</sup></td> </tr> <tr> <td>Timing of platelet count fall</td> <td>Clear onset between days 5 and 10 OR platelet fall \u2264 1 day (prior heparin exposure within 30 days)</td> <td>Consistent with days 5\u201310 fall, but not clear (e.g. missing platelet counts) OR onset after day 10 OR fall \u2264 1 day (prior heparin exposure 30\u2013100 days ago)</td> <td>Platelet count fall &lt; 4 days without recent heparin exposure</td> </tr> <tr> <td>Thrombosis or other sequelae</td> <td>New thrombosis (confirmed) OR skin necrosis at heparin injection sites OR acute systemic reaction after intravenous heparin bolus</td> <td>Progressive or recurrent thrombosis or nonnecrotizing (erythematous) skin lesions or suspected thrombosis (not proven)</td> <td>None</td> </tr> <tr> <td>Other causes for thrombocytopenia</td> <td>None apparent</td> <td>Possible</td> <td>Definite</td> </tr> </tbody> </table> </div>", "references_list": {"Original/Primary Reference": [{"href": "http://www.ncbi.nlm.nih.gov/pubmed/16634744", "text": "Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 Ts) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759\u201365."}], "Validation": [{"href": "http://www.ncbi.nlm.nih.gov/pubmed/23322137", "text": "Vatanparast R, Lantz S, Ward K, Crilley PA, Styler M. Evaluation of a pretest scoring system (4Ts) for the diagnosis of heparin-induced thrombocytopenia in a university hospital setting. Postgrad Med. 2012 Nov;124(6):36-42."}]}}, "contributor": {"expert_name": [{"description": "<p>Calvin Hwang, MD, is a clinical assistant professor in the department of orthopaedic surgery at the Stanford University School of Medicine. A native Californian, Dr. Hwang grew up in San Diego and attended Stanford University before venturing off to Case Western Reserve University School of Medicine, where he received his medical degree. He completed his residency at the Stanford/Kaiser Emergency Medicine program and fellowship in sports medicine at Stanford. He is currently a team physician for the Golden State Warriors, Stanford Football and Stanford Volleyball.</p>", "firstName": "Calvin", "img": "calvin-hwang.jpg", "lastName": "Hwang", "name": "Calvin Hwang, MD", "target": "calvin-hwang", "signedCOI": true, "hasDisclosure": []}]}, "creator": [{"name": "Dr. Andreas Greinacher", "qa_en": "", "creator_info": {"about_en": "<p>Andreas Greinacher, MD, is the head of the Institute of Immunology and Transfusion Medicine at the University Hospital Greifswald, Germany. He has interests in hereditary and acquired platelet disorders, bridging immuno-hematology and hemostasis. His recent work is on adopting nanotechnology and biophysical methods to investigate platelets and protein changes.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-andreas-greinacher.jpeg", "pubmedLink": "http://www.ncbi.nlm.nih.gov/pubmed/?term=Greinacher+A%5BAuthor%5D"}}], "how_to_use": {"pearls_pitfalls_en": "<p>The 4Ts for the diagnosis of heparin-induced thrombocytopenia (HIT) is a tool developed to help clinicians rule out HIT in patients who develop thrombocytopenia in the clinical setting.</p> <ul> <li>Included patients being evaluated for thrombocytopenia or suspected HIT in two clinical settings: inpatients at Hamilton General Hospital (HGH) in Canada and various clinicians in a variety of healthcare settings in Germany and Austria.</li> <li>The study prospectively applied previously developed scoring systems using various clinical features of HIT.</li> <li>Scoring system consisted of four criteria, each of which was worth 0, 1, or 2 points.</li> <li>Study used \u2264 3 points to define low probability group (\u22645%) for HIT, 4-5 points for intermediate and 6-8 points for high.</li> <li>Gold standard for diagnosis of HIT was either: <ul> <li>A platelet serotonin release assay (SRA) and a PF4/polyanion-enzyme immunoassay (EIA) with \u2265 50% serotonin release and positive EIA, OR</li> <li>A positive heparin-induced platelet activation (HIPA) test in at least three of four donor platelets.</li> </ul> </li> </ul> <p><strong>Points to keep in mind:</strong></p> <ul> <li>Scoring system criteria for HIT was slightly different between the two main sites.</li> <li>The study used two different tests to diagnose HIT, depending on the site.</li> <li>One of the four components of their scoring system, other causes for thrombocytopenia, is subjective.</li> <li>Results between the two sites in the intermediate and high probability groups were statistically different.</li> </ul> <p>A subsequent review and meta-analysis of the 4Ts scoring system for HIT found that patients in the low-risk group had a negative predictive value of 0.998, irrespective of type of clinician, prevalence of HIT, or patient population.</p>", "use_case_en": "<ul> <li>Consider using the 4Ts scoring system to stratify patients\u2019 risk for HIT in patients with thrombocytopenia who are currently or were recently on heparin derived agents.</li> <li>Patients falling into the low-risk category frequently do not need further testing for HIT.</li> <li>Consider further laboratory evaluation for HIT or switching to a non-heparin derived anti-coagulant in those patients in the intermediate or high-risk groups.</li> </ul>", "why_use_en": "<p>Consider using the 4Ts scoring system as an alternative evaluation tool prior to time-consuming antibody testing for HIT or empiric substitution of heparin for another anti-coagulant.</p> "}, "next_steps": {"advice_en": "", "critical_actions_en": "<ul> <li>\u22643 points: low probability for HIT (\u22645% in original study, &lt;1% in meta-analysis).</li> <li>4-5 points: intermediate probability (~14% probability of HIT).</li> <li>6-8 points: high probability (~64% probability of HIT).</li> </ul> ", "management_en": ""}}, "disease_en": ["Bleeding/Hemorrhage", "Thrombocytopenia"], "favorite_id": 1787, "full_title_en": "4Ts Score for Heparin-Induced Thrombocytopenia", "input_schema": [{"default": 2, "label_en": "Thrombocytopenia", "options": [{"label": "Platelet count fall >50% AND platelet nadir \u226520", "value": 2}, {"label": "Platelet count fall 30\u201350% OR platelet nadir 10\u201319", "value": 1}, {"label": "Platelet count fall <30% OR platelet nadir <10", "value": 0}], "show_points": true, "type": "radio", "name": "thrombocytopenia", "optional": false}, {"default": 2, "label_en": "Timing of platelet count fall", "options": [{"label": "Clear onset between days 5\u201310 OR platelet fall \u22641 day (prior heparin exposure within 30 days)", "value": 2}, {"label": "Consistent with days 5\u201310 fall, but not clear; onset after day 10 OR fall \u22641 day (prior heparin exposure 30\u2013100 days ago)", "value": 1}, {"label": "Platelet count fall <4 days without recent exposure", "value": 0}], "show_points": true, "type": "radio", "name": "platelet_fall_timing", "optional": false}, {"default": 2, "label_en": "Thrombosis or other sequelae", "options": [{"label": "New thrombosis OR skin necrosis; acute systemic reaction post-IV heparin bolus", "value": 2}, {"label": "Progressive OR recurrent thrombosis; non-necrotizing skin lesions; suspected thrombosis (not proven)", "value": 1}, {"label": "None", "value": 0}], "show_points": true, "type": "radio", "name": "thrombosis", "optional": false}, {"default": 2, "label_en": "Other causes for thrombocytopenia", "options": [{"label": "None apparent", "value": 2}, {"label": "Possible", "value": 1}, {"label": "Definite", "value": 0}], "show_points": true, "type": "radio", "name": "other_causes_thrombocytopenia", "optional": false}], "instructions_en": "", "medium_description_en": "Differentiates patients with HIT from those with other causes of thrombocytopenia.", "purpose_en": ["Diagnosis"], "search_abbreviation_en": ["plt", "HIT"], "seo": {"meta_description_en": "The 4Ts Score is a clinical scoring system to differentiate patients with HIT from those with other causes of thrombocytopenia.", "keywords_en": "4 Ts for HIT, HIT calculator, heparin score, diagnosis HIT calc, heparin induced calculator, heparin coagulopathy score, heparin thrombocytopenia score"}, "short_description_en": "HIT vs other causes of thrombocytopenia.", "short_title_en": "4Ts for HIT", "slug": "4ts-score-heparin-induced-thrombocytopenia", "specialty_en": ["Critical Care", "Emergency Medicine", "Hematology and Oncology", "Hospitalist Medicine"], "system_en": ["Hematologic"], "calc_type": "calculator", "dosing": false, "before_use": "", "md5": "0483d560043c355df74af2ff2c3337b7", "cmeVersion": "1787.1", "related_calcs": [{"calcId": 1789, "short_title_en": "HIT Expert Probability (HEP) Score", "slug": "hit-expert-probability-hep-score-heparin-induced-thrombocytopenia"}, {"calcId": 4034, "short_title_en": "Corrected Count Increment (CCI) ", "slug": "corrected-count-increment-cci-platelet-transfusion"}, {"calcId": 10203, "short_title_en": "ISTH Criteria for DIC", "slug": "isth-criteria-disseminated-intravascular-coagulation-dic"}]}